PR95775

SEOUL, Korea, May 9, 2022 /PRNewswire=KYODO JBN/ --

-To lay a technological foundation for developing exosome-based medicines and

cosmetic products for dermatitis treatment

-To prove the technological feasibility of ExoSCRT(TM) for the mass-production

of the world's best exosomes with high efficacy

ExoCoBio Inc., one of global top 4 for stem cell exosome industry, announced

that it received from Japanese Patent Office the patent which claims that stem

cell-derived exosome is proved as effective ingredient for alleviating

dermatitis (The registration number is 6970459).

The patent is the result of the vigorous R&D efforts made to develop

therapeutic medicines with higher efficacy and safety than currently known ones

in relation to dermatitis with itching and inflammation. ExoCoBio found that

the technology in the patent would solve the safety problem arising from stem

cell or stem cell conditioned media by using ExoSCRT(TM) exosomes isolated from

adipose stem cell conditioned media and thus prove the effectiveness of

exosomes for prevention, improvement, alleviation or treatment of dermatitis.

Furthermore, it is anticipated that the ExoSCRT(TM) exosomes will play a

scientifically pivotal role as new medicine for dermatitis treatment.

Among therapeutic medicines currently marketed for the dermatitis are steroid,

antihistamine, and immunosuppressive cyclosporine A etc. There are, however,

growing concerns about serious side effects in relation with the use of them

such as atrophodermia, vasodilation, loss of pigment, hypersensitivity after

injection, tolerance and neutropenia etc. On the contrary, exosome-based

medicines are expected to provide the fundamental treatment for inflammatory

skin diseases without any serious side effect.

The key points of the patent cover following:

-ExoSCRT(TM) exosomes reduce the generation of inflammatory factors including

inflammatory cytokine which are main causes of dermatitis;

-ExoSCRT(TM) exosomes can be developed as active principles of medicine or

cosmetics to prevent, alleviate or treat the dermatitis by suppressing the

activity of inflammatory immune cells;

-ExoSCRT(TM) exosomes promote the ceramide biosynthesis that is a key factor of

skin barrier;

-It was scientifically proved that ExoSCRT(TM), technology developed by

ExoCoBio for stem cell exosome production, plays a key role in producing high

quality exosomes;

In connection with the patent, ExoCoBio published an article in the journal of

Stem Cell Research & Therapy in 2018 according to which ExoSCRT(TM) exosomes

alleviate atopic dermatitis with antibodies against surface markers (CD9, CD63,

and CD81) (for the article, please visit the following:

https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-0939-5).

Additionally, as a supporting document, ExoCoBio published an article in the

journal of Cells in 2020, according to which ExoSCRT(TM) exosomes promote de

novo synthesis of ceramides in atopic dermatitis (for the article, visit the

following: https://pubmed.ncbi.nlm.nih.gov/32164386/).

ExoCoBio expects that the patent will lay a technological foundation for

regenerative aesthetics and medicines relating to prevention, alleviation or

treatment of dermatitis. Furthermore, ExoCoBio anticipates its business

opportunity in Japan for ExoSCRT(TM) exosomes based on the patent in the

cosmetic and pharmaceutical fields.

SOURCE: ExoCoBio Inc.